Discover.
Launch.
Build.
Transform.

Terremoto Biosciences

Terremoto is harnessing covalent chemistry to discover and develop small molecule medicines.

Terremoto Biosciences

MyoKardia

Bristol Myers Squibb (BMS) received approval from the U.S. FDA for Camzyos® (mavacamten). Camzyos, the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source of obstructive hypertrophic cardiomyopathy, was originally developed by Third Rock portfolio company, MyoKardia, which was acquired by BMS in 2020.

Septerna

Septerna is creating broad new drug discovery opportunities across many disease areas for the abundant drug target class of GPCRs.

Septerna

bluebird bio

bluebird bio and Bristol Myers Squibb received approval from the U.S. Food and Drug Administration (FDA) for Abecma® (idecabtagene vicleucel) as the first CAR T cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma.

bluebird bio

Living our core values.

One of Third Rock’s founding core values is to do the right thing. We believe diversity fuels innovation and are committed to fostering inclusion and diversity in all we do. That's why we are proud to be one of the founding members of the Bioscience & Investor Inclusion Group (BIIG), a coalition created to address diversity, equity and inclusion in the life sciences sector.

Learn More
15

Years

60

Portfolio Companies

18

Marketed Products

1

Priority: Patients